Platelets are activated at sites of vascular injury via several molecules, such as adenosine diphosphate, collagen and thrombin. Full platelet aggregation is absolutely essential for normal hemostasis. Moreover, this physiological event can trigger circulatory disorders, such as thrombosis, atherosclerosis, and cardiovascular disease. Therefore, platelet function inhibition is a promising approach in preventing platelet-mediated circulatory disease. Many studies reported the involvement of mitogen-activated protein kinases (MAPKs) signaling pathways in platelet functions. However, these studies were limited. Thus, we examined MAPK signaling pathways in human platelets using specific MAPK inhibitors, such as PD98059, SB203580, and SP600125. We observed that these inhibitors were involved in calcium mobilization and influx in human platelets. They also suppressed thrombin-induced α-and δ-granule release. These results suggest that PD98059, SB203580, and SP600125 exhibit Ca 2+ antagonistic effects.
INTRODUCTION
Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine protein kinases that are divided into three subgroups: extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38. Studies have detected MAPKs in human platelets and have shown them to be phosphorylated by thrombin for full activation Bugaud et al., 1999; Nadal-Wollbold et al., 2002) .
Furthermore, the roles of MAPKs have been studied in hemostasis and thrombosis (Adam et al., 2008) . In platelets, ERKs have been extensively investigated among MAPKs.
ERKs may be activated via growth factors, receptor tyrosine kinases and G protein-coupled receptors in various cell types (van Blesen et al., 1995) . Its signaling process is initiated by the small G protein Ras, which activates the Raf-1/MAPK/ ERK (MEK)/ERK phosphorylation pathway (Kyriakis et al., 1992) . ERK2 is reportedly activated by the dual-specificity kinase, MEK1/2, and protein kinase C (PKC)-dependent pathway in platelets (Börsch-Haubold et al., 1995; Börsch-Haubold et al., 1996) . Regarding the ERK1/2 upstream molecule specific inhibitors of conventional PKCs (Ro-318425 and Ro-318220) reportedly inhibit MEK1/2 and ERK1/2 (Börsch-Haubold et al., 1995; Nadal-Wollbold et al., 2002) .
Furthermore, H-Ras and Raf-1 in the platelets do not influence ERK1/2 activation (Nadal-Wollbold et al., 2002) . A specific PKCδ inhibitor (Rottlerin) also reportedly suppresses the thrombin-induced phosphorylation of MEK1/2, ERK1/2, and p38 (Yacoub et al., 2006) . Src kinase inhibitor PP2 and phospholipase C inhibitor U73122, have also been shown to inhibit the von Willebrand factor induced ERK2 phosphorylation (Ramakrishnan et al., 2001) . Considering these previous reports, it appears that ERK2 may be regulated by PKCα and PKCδ. Furthermore, the study of JNK1 in platelets has identified, a key role for it in platelet function and thrombosis (Adam et al., 2010) . JNK1-deficient mice were shown to reduce thromboxane A 2 (TXA 2 ) production despite normal platelet counts, ultrastructures, and expression of adhesive receptors such as GPIbα, GPVI, and glycoprotein IIb/IIIa (αIIb/β3). Moreover, JNK1
-/-showed diminished ERK2 levels after thrombin stimulation, which suggested that JNK1 may be an upstream molecule of ERK2 or at least associated with each other (Adam et al., 2010) . Thrombinactivated ERK2 and JNK1 were also reportedly downregulated by αIIb/β3 inhibition, which suggested that the activation probably involved a common pathway (Bugaud et al., 1999) .
p38 is activated by thrombin and the phospholipases Cβ, and PKCδ, are known as upstream mediators (Yacoub et al., 2006) . Activated p38 increases the phosphorylation of cytosolic phospholipase A 2 , resulting in arachidonic acid release and TXA 2 production; however, SB203580 inhibits TXA 2 production .
Furthermore, PD98059 and SB203580, specific inhibitors of ERK1/2 and p38, block COX-1 directly and SB203580
further inhibits the conversion of PGH 2 to TXA 2 (Börsch-Haubold et al., 1998) , which means that MAPKs may influence endogenous enzyme activity leading to TXA 2 production. Various studies have revealed the MAPK functions in platelets; however, their complete regulatory functions have been elusive. Therefore, we investigated MAPK signaling pathways in human platelet using specific inhibitors. 
MATERIALS AND METHODS

Materials
Determination of platelet aggregation
Platelets (10 8 /mL) were preincubated with or without substances in the 2 mM CaCl 2 for 3 min at 37℃ followed by thrombin stimulation (0.05 U/mL). The aggregation was performed for 5 min using an aggregometer (Chrono-Log Corporation). Platelet aggregation rate was determined as an increase in light transmission. MAPK inhibitors were dissolved in dimethyl sulfoxide (DMSO) to a final concentration of 0.1%.
Western blots for analyzing of ERK1/2-, p38-, and
JNK1/2-phosphorylation
Platelet aggregation was stopped by adding 1× lysis -255 -buffer. The platelet lysates were then measured using a BCA protein assay kit (Pierce Biotechnology, IL, USA). Proteins (15 μg) were analyzed via SDS-PAGE (6%, 1.5 mm), and PVDF membranes were used for protein transfer. The dilutions for the primary and secondary antibodies were 1:1,000
and 1:10,000, respectively. The membranes were visualized using the ECL solution. ] i values were calculated using the Grynkiewicz method (Grynkiewicz et al., 1985) .
Determination of Ca
Determination of p-selectin release
Washed human platelets (10 8 /mL) were preincubated with or without substances in the presence of 2 mM CaCl 2 for 3 min at 37℃ followed by thrombin stimulation (0.05 U /mL). The platelets were reconstituted in 250 μL of ice-cold phosphate-buffered saline (PBS; pH 7.4) and incubated with 10 μL of Alexa Fluor 488 anti-human CD62P in PBS (pH 7.4) containing 0.09% sodium azide and 0.2% bovine serum albumin (BSA) for 60 min at 4℃ in a dark room.
The platelets were then washed thrice with ice-cold PBS and resuspended in 0.5% paraformaldehyde in PBS. The platelet-bound Alexa Fluor 488 anti-human CD62P was determined using flow cytometry (BD Biosciences, San Diego, CA, USA) and the data was analyzed using the BD cellQuest TM software.
Determination of ATP and serotonin release
Washed platelets (10 8 /mL) were stimulated with thrombin (0.05 U/mL) with or without MAPK inhibitors in the presence of 2 mM CaCl 2 . The reaction was terminated and centrifuged at 200 ×g for 10 min at 4℃, and the supernatant was used for ATP and serotonin release assay. ATP and serotonin release were measured using a Synergy HT MultiMode Microplate Reader (BioTek Instruments, Winooski, VT, USA).
Statistical analyses
The experimental results are indicated as mean ± standard deviation accompanied by the number of observations. The data was determined via analysis of variance (ANOVA).
Significant differences among the group means were compared using the Newman-Keuls method. Statistical analysis was performed using SPSS 21.0.0.0 (SPSS, Chicago, IL, USA). P < 0.05 was considered to be statistically significant.
RESULTS
Effects of MAPK inhibitors on thrombin-induced human platelet aggregation
Based on a previous report, 0.05 U/mL of thrombin was used as it maximally aggregated human platelets (Shin et al., 2015) . The thrombin-induced aggregation rate was 92.5 ± 1.2%, however, PD98059, SB203580 and SP600125 at 20 μM could not inhibit thrombin-induced platelet aggregation (Fig. 1A) . Thus, we used 40 μM of the MAPK inhibitors on thrombin-induced platelet aggregation. As shown in Fig. 1A , PD98059, SB203580 and SP600125 at 40 μM suppressed human platelet aggregation. Therefore, we used these concentrations to evaluate anti-platelet effects.
Effects of MAPK inhibitors on ERK1/2-, p38, and JNK1/2-phosphorylation
MAPK phosphorylation is known to be positively regulated in human platelet aggregation. Thus, we examined if PD98059, SB203580, and SP600125 inhibited the MAPK phosphorylation. Compared to unstimulated platelets thrombin (0.05 U/mL) elevated ERK2-, p38-, and JNK1-phosphorylation (Fig. 1B, 1C, and 1D ). However, 40 μM of PD98059, SB203580, and SP600125 reduced ERK2-, p38-, and JNK1-phosphorylation. Furthermore, 0.1% DMSO did not influence phosphorylation (Fig. 1B, 1C , and 1D).
Effects of MAPK inhibitors on [Ca
2+ ] i mobilization
We investigated the effect of PD98059, SB203580 and SP600125 on Ca 2+ antagonistic activity. As shown in Fig.   2A , thrombin-increased Ca 2+ mobilization from 100.5 ± 1.3 nM to 835.9 ± 39.7 nM in the presence of 2 mM CaCl 2 .
However, we eliminated the indirect effects of Ca 2+ influx to accurately measure [Ca 2+ ] i mobilization by using EGTA (100 μM), which was recorded as 370.5 ± 1.1 nM (Fig.   2B ). Thrombin-induced [Ca 2+ ] i mobilization suppressed PD-98059, SB203580, and SP600125 (Fig. 2C, 2D , and 2E).
The percentage inhibition by 40 μM of MAPK inhibitors were 33.6%, 36.2%, and 57.4%, respectively (Table 1) .
Effects of MAPK inhibitors on IP 3 RI-phosphorylation
IP 3 receptor type I (IP 3 RI) phosphorylation leads to the inhibition of [Ca 2+ ] i mobilization (Quinton and Dean, 1992 ] i mobilization.
Effects of MAPK inhibitors on [Ca
2+ ] i influx
Thapsigargin is an inhibitor of the sarco/endoplasmic reticulum Ca 2+ ATPase, which is used to trigger Ca 2+ influx Platelet aggregation and Western blots were carried out as described in the "Materials and Methods" section. The data is expressed as mean ± standard deviation (n = 4). *P < 0.05 versus thrombinstimulated human platelets.
from extracellular spaces. after adding 2 mM CaCl 2 , 1 μM of thapsigargin triggers Ca 2+ influx from 101.5 ± 1.2 nM (the basal level) to 860.5 ± 21.2 nM (Fig. 4A) . However, 40 μM of PD98059, SB203580, and SP600125 inhibits Ca 2+ influx (Fig. 4B, 4C , and 4D). The percentage inhibition by 40 μM of MAPK inhibitors were observed to be 67.0%, 69.5%, and 78.9%, respectively ( Table 2) .
Effects of MAPK inhibitors on p-selectin expression
In order to verify the inhibitory mechanism of PD98059, SB203580 and SP600125 on α-granule release, we investigated p-selectin expression. PD98059, SB203580, and SP- ] i mobilization was determined as described in the "Materials and Methods" section. The data is expressed as mean ± standard deviation (n = 3). *P < 0.05 versus thrombin-stimulated human platelets.
( Fig. 5A and 5B), which reflected their inhibitory effect on [Ca 2+ ] i levels. The intracellular Ca 2+ chelator, BAPTA-AM also strongly suppressed thrombin-induced p-selectin expression ( Fig. 5A and 5B).
Effects of MAPK inhibitors on ATP and serotonin release
Since the MAPK inhibitors decreased the thrombin- Data is expressed as mean ± standard deviation (n = 4). *P < 0.05 versus thrombin-stimulated human platelets. 2+ influx in the presence of EGTA (100 μM). Ca 2+ influx was determined as described in the "Materials and Methods" section.
Fig. 3 Effects of MAPK inhibitors on IP 3 RI-phosphorylation.
Western blots were analyzed as described in the "Materials and Methods" section. The data is expressed as mean ± standard deviation (n = 3).
-259 -elevated [Ca 2+ ] i levels, we investigated the involvement of the MAPK signaling pathways in the inhibition of ATP and serotonin release from δ-granules. Thrombin (0.05 U/mL) strongly increased ATP (Fig. 6A ) and serotonin release (Fig.   6B) ; however, all the MAPK inhibitors suppressed ATP and serotonin release. Moreover, BAPTA-AM decreased ATP and serotonin release, indicating the involvement of intracellular Ca 2+ levels in granule release ( Fig. 6A and 6B ). Data is expressed as mean ± standard deviation (n = 4). *P < 0.05 versus thapsigargin-stimulated human platelets. . Determination of p-selectin expression was carried out as described in the "Materials and Methods" section. The data is expressed as mean ± standard deviation (n = 3). *P < 0.05 versus thrombin-stimulated human platelets.
DISCUSSION
(PIP 2 ) to inositol 1, 4, 5-trisphosphate (IP 3 ) and diacylglycerol (Berridge and Irvine, 1984; Cattaneo, 2005; Guidetti et al., 2008; Jennings, 2009 Therefore, the increase of calcium plays an important role in inducing the granule secretion (i.e., dense body and α-granule) and platelet aggregation (Nishikawa et al., 1980; Kaibuchi et al., 1982) .
IP 3 RI function is inhibited by its phosphorylation and IP 3 RI phosphorylation involves in the inhibition of [Ca 2+ ] i mobilization (Quinton and Dean, 1992 (Lopez et al., 2012; Lang et al., 2013) , and thapsigargin was reported to trigger STIM1 tyrosine phosphorylation in human platelets (Lopez et al., 2012) . Moreover, both ERK1/2 and the Src family of tyrosine kinases were reported to be involved in STIM1 phosphorylation (Elvers et al., 2012; Lopez et al., 2012 ] i influx ( Fig. 4C and 4D ). These Determination of ATP and serotonin release was carried out as described in the "Materials and Methods" section. The data is expressed as mean ± standard deviation (n = 3). * P < 0.05 versus thrombin-stimulated human platelets.
results suggested that the JNK and p38 signaling pathways were also involved in Ca 2+ influx. To date, the relationship between stim1 and MAPKs has been reported in various cells and ERK is most closely related. However, in our experiments, it was suggested that p38 and JNK also downregulated thapsigargin-induced calcium influx in human platelets, which means that p38 and JNK may interact with STIM1. Thus, the specific interaction between JNK, p38, and STIM1 in human platelets will be tested in the future.
MAPK inhibitors showed a potent calcium inhibitory effect (20, 40 μM) but did not suppress at low concentrations in human platelet aggregation reactions (Fig. 1A) . Because the platelet aggregation reaction is the final reaction, a variety of signal transduction processes trigger the final platelet aggregation reaction. MAPK inhibitors could affect the detailed signaling of platelets, but the inhibitory effects may be limited. Therefore, MAPK inhibitors (20 μM) could not have a strong effect on the final platelet aggregation inhibition.
The markers of α-and δ-granule release used in this study are p-selectin, ATP, and serotonin. p-selectin is located in the inner membrane of α-granule, and ATP, serotonin are located in the δ-granule. Therefore, we examined the MAPK signaling pathways that were associated with α-and δ-granule release. Thrombin-elevated p-selectin expression (Fig.   5A , 5B) and ATP and serotonin release (Fig. 6A, 6B ). However, these reactions were inhibited by MAPK inhibitors.
Because [Ca
2+
] i is the most important regulator of α-and δ-granule release, p-selectin expression, ATP and serotonin release are also dependent on [Ca 2+ ] i levels. This result reflects that BAPTA-AM (10 μM) treated platelets significantly downregulated the p-selectin expression (Fig. 5A-g , 5B), ATP, and serotonin release (Fig. 6A, 6B ). Therefore, these inhibitory effects on α-and δ-granule release by MAPK ] i influx.
In conclusion, the precise mechanism of the MAPK signaling pathway is still not fully understood. However, our results suggest that the MAPK signaling pathway plays a role in α-and δ-granule release by down-regulating Ca 
